875 related articles for article (PubMed ID: 18349518)
1. Different tau pathology pattern in two clinical phenotypes of progressive supranuclear palsy.
Jellinger KA
Neurodegener Dis; 2008; 5(6):339-46. PubMed ID: 18349518
[TBL] [Abstract][Full Text] [Related]
2. Clinical and neuropathologic features of progressive supranuclear palsy with severe pallido-nigro-luysial degeneration and axonal dystrophy.
Ahmed Z; Josephs KA; Gonzalez J; DelleDonne A; Dickson DW
Brain; 2008 Feb; 131(Pt 2):460-72. PubMed ID: 18158316
[TBL] [Abstract][Full Text] [Related]
3. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome.
Williams DR; Holton JL; Strand C; Pittman A; de Silva R; Lees AJ; Revesz T
Brain; 2007 Jun; 130(Pt 6):1566-76. PubMed ID: 17525140
[TBL] [Abstract][Full Text] [Related]
4. A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease.
Halliday GM; Macdonald V; Henderson JM
Brain; 2005 Oct; 128(Pt 10):2272-80. PubMed ID: 16014651
[TBL] [Abstract][Full Text] [Related]
5. Cerebellar involvement in progressive supranuclear palsy: A clinicopathological study.
Kanazawa M; Shimohata T; Toyoshima Y; Tada M; Kakita A; Morita T; Ozawa T; Takahashi H; Nishizawa M
Mov Disord; 2009 Jul; 24(9):1312-8. PubMed ID: 19412943
[TBL] [Abstract][Full Text] [Related]
6. Lewy bodies in progressive supranuclear palsy represent an independent disease process.
Uchikado H; DelleDonne A; Ahmed Z; Dickson DW
J Neuropathol Exp Neurol; 2006 Apr; 65(4):387-95. PubMed ID: 16691119
[TBL] [Abstract][Full Text] [Related]
7. Cortical atrophy differentiates Richardson's syndrome from the parkinsonian form of progressive supranuclear palsy.
Schofield EC; Hodges JR; Macdonald V; Cordato NJ; Kril JJ; Halliday GM
Mov Disord; 2011 Feb; 26(2):256-63. PubMed ID: 21412832
[TBL] [Abstract][Full Text] [Related]
8. Progressive supranuclear palsy and corticobasal degeneration: lumping versus splitting.
Scaravilli T; Tolosa E; Ferrer I
Mov Disord; 2005 Aug; 20 Suppl 12():S21-8. PubMed ID: 16092076
[TBL] [Abstract][Full Text] [Related]
9. Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata.
Hardman CD; Halliday GM; McRitchie DA; Cartwright HR; Morris JG
Exp Neurol; 1997 Mar; 144(1):183-92. PubMed ID: 9126169
[TBL] [Abstract][Full Text] [Related]
10. [A 65-year-old man with rigid-bradykinetic parkinsonism, vertical gaze palsy, difficulty of eye-lid opening, and marked pseudo-bulbar palsy].
Noda K; Kobayashi T; Matsuoka S; Takanashi M; Kanazawa A; Mizuno Y
No To Shinkei; 2005 Jan; 57(1):73-86. PubMed ID: 15782604
[TBL] [Abstract][Full Text] [Related]
11. Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome.
Tsuboi Y; Josephs KA; Boeve BF; Litvan I; Caselli RJ; Caviness JN; Uitti RJ; Bott AD; Dickson DW
Mov Disord; 2005 Aug; 20(8):982-8. PubMed ID: 15834857
[TBL] [Abstract][Full Text] [Related]
12. The internal globus pallidus is affected in progressive supranuclear palsy and Parkinson's disease.
Hardman CD; Halliday GM
Exp Neurol; 1999 Jul; 158(1):135-42. PubMed ID: 10448425
[TBL] [Abstract][Full Text] [Related]
13. Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy.
Borroni B; Malinverno M; Gardoni F; Alberici A; Parnetti L; Premi E; Bonuccelli U; Grassi M; Perani D; Calabresi P; Di Luca M; Padovani A
Neurology; 2008 Nov; 71(22):1796-803. PubMed ID: 18971445
[TBL] [Abstract][Full Text] [Related]
14. Lewy bodies in progressive supranuclear palsy.
Mori H; Oda M; Komori T; Arai N; Takanashi M; Mizutani T; Hirai S; Mizuno Y
Acta Neuropathol; 2002 Sep; 104(3):273-8. PubMed ID: 12172913
[TBL] [Abstract][Full Text] [Related]
15. Cerebellar cortical tau pathology in progressive supranuclear palsy and corticobasal degeneration.
Piao YS; Hayashi S; Wakabayashi K; Kakita A; Aida I; Yamada M; Takahashi H
Acta Neuropathol; 2002 May; 103(5):469-74. PubMed ID: 11935262
[TBL] [Abstract][Full Text] [Related]
16. Neuropathology of variants of progressive supranuclear palsy.
Dickson DW; Ahmed Z; Algom AA; Tsuboi Y; Josephs KA
Curr Opin Neurol; 2010 Aug; 23(4):394-400. PubMed ID: 20610990
[TBL] [Abstract][Full Text] [Related]
17. Early-stage progressive supranuclear palsy with degenerative lesions confined to the subthalamic nucleus and substantia nigra.
Sakai K; Yamada M
Neuropathology; 2011 Feb; 31(1):77-81. PubMed ID: 20573028
[TBL] [Abstract][Full Text] [Related]
18. The evolution and pathology of frontotemporal dementia.
Kertesz A; McMonagle P; Blair M; Davidson W; Munoz DG
Brain; 2005 Sep; 128(Pt 9):1996-2005. PubMed ID: 16033782
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP.
Josephs KA; Petersen RC; Knopman DS; Boeve BF; Whitwell JL; Duffy JR; Parisi JE; Dickson DW
Neurology; 2006 Jan; 66(1):41-8. PubMed ID: 16401843
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism.
Williams DR; de Silva R; Paviour DC; Pittman A; Watt HC; Kilford L; Holton JL; Revesz T; Lees AJ
Brain; 2005 Jun; 128(Pt 6):1247-58. PubMed ID: 15788542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
